07:00 , Sep 3, 2007 |  BC Week In Review  |  Company News

Emisphere management update

Emisphere Technologies Inc. (EMIS), Tarrytown, N.Y.   Business: Drug delivery   Hired: Michael Garone as CFO, formerly CFO and interim CEO of Astralis Ltd.  ...
07:00 , Oct 16, 2006 |  BC Week In Review  |  Company News

Astralis autoimmune, dermatology news

ASTR said it will discontinue its drug development activities and is considering strategic alternatives, including selling its assets. In August, the company said its liabilities had exceeded its cash, and that it would cease operations...
07:00 , May 2, 2005 |  BC Week In Review  |  Company News

Astralis board of directors update

Astralis Ltd. (ASTR), Fairfield, N.J.   Business: Autoimmune, Dermatology   Appointed: Gordon Schooley, CSO of SkyePharma plc  ...
08:00 , Mar 21, 2005 |  BC Week In Review  |  Clinical News

Psoraxine: Preliminary Phase II data

Preliminary data from a double-blind, placebo-controlled, U.S. Phase II trial in 120 patients showed that 6 injections of Psoraxine over 12 weeks of treatment did not improve the PASI scores, the primary endpoint. ASTR will...
02:44 , Mar 15, 2005 |  BC Extra  |  Clinical News

Astralis' Psoraxine fails Phase II

ASTR's Psoraxine missed the primary endpoint of PASI score improvements in a double-blind, placebo-controlled, U.S. Phase II trial in 120 patients with moderate to severe psoriasis. ASTR said it will continue to develop the compound,...
08:00 , Feb 15, 2005 |  BC Extra  |  Company News

Astralis names Sharpe CEO

ASTR hired James Sharpe as CEO. Sharpe, previously president of Ankyr Consulting, takes over for chairman Jose O'Daly, who had been serving as interim CEO since last July. The company's Psoraxine, a protein extract of...
08:00 , Dec 20, 2004 |  BC Week In Review  |  Company News

Astralis, SkyePharma deal

SKP will buy 11.2 million ASTR shares from former directors in exchange for 6 million shares of SKP. The agreement is subject to the negotiation of definitive agreements and the appointment of additional directors nominated...
07:00 , Sep 27, 2004 |  BC Week In Review  |  Clinical News

Psoraxine: Phase II completed enrollment

ASTR completed enrollment of 120 patients in a double-blind, placebo-controlled U.S. Phase II trial. Patients will receive intramuscular injections once every 2 weeks for 3 months. Astralis Ltd. (ASTR), Fairfield, N.J.   Product: Psoraxine  ...
07:00 , Aug 9, 2004 |  BC Week In Review  |  Clinical News

Psoraxine: Phase I data

In a double-blind, placebo-controlled, U.S. Phase I trial in 21 patients, Psoraxine was well tolerated at single doses of 50 mg, 150 mg or 300 mg. At day 14, more patients receiving Psoraxine showed improved...
07:00 , Aug 9, 2004 |  BC Week In Review  |  Clinical News

Psoraxine: Phase II ongoing

ASTR disclosed it began in April a 3-month, placebo-controlled U.S. Phase II trial in 120 patients. The company expects to complete enrollment this month. Astralis Ltd. (ASTR), Fairfield, N.J.   Product: Psoraxine   Business: Autoimmune...